The TELIGEN System is said to be an integrated technology platform which uses digital tools for visualisation and access
DePuy Synthes is Johnson & Johnson’s orthopaedics company. (Credit: user:ekem from Wikimedia Commons)
Johnson & Johnson’s orthopaedics company DePuy Synthes has obtained the US Food and Drug Administration (FDA) 510(k) clearance for its TELIGEN System, designed for minimally invasive surgical transforaminal lumbar interbody fusion (MIS-TLIF) procedures.
The TELIGEN System is said to be an integrated technology platform which uses digital tools for visualisation and access. It features a tower that includes a camera control system, a VueLIF-T procedure kit with a disposable HD camera, a TELIGEN Clear Discectomy Device, and patient-based disposable ports.
According to Johnson & Johnson MedTech, the system integrates with the UNLEASH bundle of implant solutions, which is designed to simplify the key phases in MIS-TLIF. It also offers an advanced visualisation experience and user-centric procedural control.
The TELIGEN VUE Camera, which is digitally equipped, and found at the distal end of the patient-specific port, can give an unobstructed view, multidirectional and enlarged field of view. It also provides hands-free visualisation during the surgery, said Johnson & Johnson MedTech.
Additionally, surgeons can adjust image clarity according to their preferences by using the self-cleaning camera’s LED lighting.
According to the firm, the heads-up display of the TELIGEN System enables surgeons to keep a comfortable posture while operating.
DePuy Synthes spine worldwide president Russell Powers said: “Improving the MIS spinal surgery experience for both patients and surgeons is a critical step to addressing unmet needs in the industry.
“With our groundbreaking TELIGEN Technology Platform, we’re providing a better field of view to help improve patient care and increase efficiencies.”
Based on small cadaver research, the TELIGEN System was found to speed up MIS-TLIF procedures when compared to those done under a surgical microscope by 47%, said Johnson & Johnson MedTech.
The company anticipates that the TELIGEN System will be offered in the US later this year.